Navigation Links
Healthpoint Biotherapeutics Acquires Regranex® Gel
Date:6/2/2011

rolonged, non-healing, inflammatory state). Chronic wounds are often derivative of another illness or condition such as diabetes, obesity, peripheral vascular disease and immobility.

Diabetic foot ulcers are those that occur in individuals with diagnosed diabetes mellitus with peripheral neuropathy. These wounds are considered inherently difficult-to-heal and at risk of becoming chronic due to the underlying disease state interfering with the normal healing process. The longer it takes for a wound to heal, the greater the likelihood of complications.

It is estimated that 7% or 20.8 million people have diabetes in the Unites States alone, and the incidence is expected to increase some 14% annually. Of those diagnosed with diabetes, up to 15% will develop a diabetic foot ulcer in their lifetime, and up to 59% will have recurrence of their foot ulcers, leading to over 82,000 amputations annually.  The total annual direct cost of non-infected diabetic ulcer treatment has been estimated at over $6 billion.

"Non-healing diabetic foot ulcers are the number one cause of non-traumatic amputations in the United States," said Bert Slade, MD, Chief Medical Officer of Healthpoint Biotherapeutics.  "Regranex® Gel continues to be an important option in the therapeutic armamentarium for patients with these wounds."

About Healthpoint Biotherapeutics

Healthpoint Biotherapeutics is a biopharmaceutical company focused on the development and commercialization of novel, cost-effective solutions for tissue repair and healing. The company's diversified research and development strategy is presently centered around therapeutic enzymes, biologics and next-generation cell- and cell-matrix based therapies for the prevention and treatment of acute, chronic and burn-related wounds. Currently marketed products include Collagenase SANTYL® Ointment, OASIS® Wound Matrix, OASIS® Ultra Tri-Layer Matrix and Regranex® Gel. He
'/>"/>

SOURCE Healthpoint Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Northwest Biotherapeutics to Present at American Society of Cell and Gene Therapy
2. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
3. Talecris Biotherapeutics Announces Results of Annual Stockholders Meeting
4. Talecris Biotherapeutics Announces First Quarter 2011 Results
5. Talecris Biotherapeutics to Report First Quarter 2011 Financial Results
6. Northwest Biotherapeutics Addresses Recent Market Activity
7. Talecris Biotherapeutics Announces Record Date for 2011 Annual Meeting of Shareholders
8. Talecris Biotherapeutics Announces Fourth Quarter and Full Year 2010 Results
9. Talecris Biotherapeutics Announces Teleconference and Webcast Information for Special Meeting of Shareholders
10. Talecris Biotherapeutics to Report Fourth Quarter and Full Year 2010 Financial Results
11. Talecris Biotherapeutics Announces Revised Record Date and Meeting Date for Special Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... LAWRENCEVILLE, N.J. , May 28, 2015 ... announced that it has received commitments from two institutional ... million of the Company,s common stock in an at-the-market ... warrants to purchase common stock. The Company ... pursuant to which the Company agreed to sell an ...
(Date:5/28/2015)... BioNorth Texas (BioNorthTX), an independent, non-profit ... sciences industry in northern region of Texas, held ... Foundry in Dallas on April 27, 2015. The ... broad spectrum of biotech professionals from the North ... in partnering with key life sciences organizations both ...
(Date:5/28/2015)... , May 28, 2015 Biscayne Pharmaceuticals, ... potential of its growth hormone-releasing hormone (GHRH) technology will ... 2015 ASCO Annual Meeting. The data show that the ... anti-cancer GHRH blockers, is present on many primary breast ... suggest that GHRH antagonists could have broad anti-cancer potential ...
(Date:5/28/2015)... The Fertility Centers of New England is ... has taken on a new and expanded role as ... guidance, leadership, oversight and quality assurance for the practice. ... our team of experienced reproductive endocrinologists,” said Fertility Centers ... M.D. “Her expertise and compassionate, individualized care have helped ...
Breaking Biology Technology:Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3BioNorthTX Holds Inaugural Board of Directors Meeting 2BioNorthTX Holds Inaugural Board of Directors Meeting 3Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3Danielle Vitiello, MD of Fertility Centers of New England, Named New Medical Director 2
... by Launch of Nine Emerging Therapies, Including Five Oral Agents, According ... ... Resources, WALTHAM, Mass., May 29 Decision Resources, one of the,world,s ... highly anticipated launch of the first,oral agents formally approved for multiple sclerosis ...
... Inc. (Nasdaq: MAPP ) today announced the appointment ... Vice President of Human,Resources., Mr. Rosa brings over ... recently, Mr. Rosa worked at Carl Zeiss Meditec, Inc. ... had held since May of,2002. He was an integral ...
... Incorporated,(Nasdaq: GPRO ) announced today that the Company ... specific molecular diagnostic test to detect,high-risk strains of the ... Assay has been CE marked and is currently available,for ... marking and launch of our APTIMA HPV Assay in ...
Cached Biology Technology:Oral Drug From Novartis/Mitsubishi Tanabe Will Capture the Largest Market Share of All Emerging Multiple Sclerosis Therapies in 2017 2MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources 2Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus 2Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus 3Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus 4Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus 5
(Date:5/18/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
(Date:5/11/2015)... 2015 Curemark LLC, a privately held drug ... new Phase III double blind, randomized, placebo-controlled clinical trial ... on all children ages 3-8 with Autism. Previously, Curemark ... double blinded clinical trial for CM-AT in children ages ... digestive enzyme chymotrypsin. This new trial will help determine ...
(Date:5/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, reminds investors and media that  Mr. David ... CARTES SECURE CONNEXIONS AMERICA 2015, held in Washington ... three-day conference is organized into a series of nine session ... Global Fraud: Where is the Trust in Cyberspace? and ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... plants to treat their offspring for disease, research by biologists ... 6 in the journal Ecology Letters. "We ... plants, can reduce parasite infection in the monarchs," says Jaap ... "And we have also found that infected female butterflies prefer ...
... at the Gladstone Institute of Virology and Immunology (GIVI) have ... in the liver is required for the infectious activity of ... new strategy for treating the infection. More than 160 ... is available to prevent further spread of the disease. Current ...
... at the Georgia Institute of Technology and Emory University have ... material into the body to improve the treatment of inflammatory ... become a popular research area because of its potential therapeutic ... a living organism has been an obstacle. In the ...
Cached Biology News:Study finds monarch butterflies use medicinal plants to treat offspring for disease 2Gladstone scientists link hepatitis C virus infection to fat enzyme in liver cells 2Researchers develop oral delivery system to treat inflammatory bowel diseases 2Researchers develop oral delivery system to treat inflammatory bowel diseases 3
For mRNA Differential Display with three one-base anchored oligo-dT primers and rationally designed arbitrary 13mers. These kits feature the latest generation of isotopic mRNA Differential Display t...
Request Info...
... Panomer 9 oligodeoxynucleotides are ... labeled at the 5' ... Alexa Fluor dyes and ... assessing microarray spot morphology, ...
Topoisomerase I, isolated from wheat germ, is an enzyme capable of removing negative supercoils from covalently closed circular DNA (1)....
Biology Products: